Cytokinetics (CYTK) News Today $38.56 -1.25 (-3.14%) Closing price 04:00 PM EasternExtended Trading$38.72 +0.16 (+0.43%) As of 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period ExodusPoint Capital Management LP Has $439,000 Position in Cytokinetics, Incorporated (NASDAQ:CYTK)ExodusPoint Capital Management LP lessened its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 92.1% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 9,324 shares of the biopharmaceutical company's stock after selling 108,660 shApril 15 at 4:21 AM | marketbeat.comBristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With ItApril 14 at 7:03 PM | investors.comCiti adds two, removes two from North America Focus ListApril 14 at 2:28 PM | markets.businessinsider.comCytokinetics, Incorporated (NASDAQ:CYTK) Receives Average Rating of "Moderate Buy" from AnalystsShares of Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eighteen ratings firms that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating, fifteen have issuedApril 14 at 1:14 AM | marketbeat.comQuinn Opportunity Partners LLC Purchases 9,302 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)Quinn Opportunity Partners LLC boosted its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 8.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 115,939 shareApril 13 at 7:52 AM | marketbeat.comCytokinetics' (CYTK) Market Outperform Rating Reiterated at JMP SecuritiesApril 13 at 3:43 AM | americanbankingnews.comGeode Capital Management LLC Has $133.69 Million Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)Geode Capital Management LLC lowered its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 0.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 2,841,338 shares of the biopharmaceutical company's stock after selling 7,246 shareApril 11, 2025 | marketbeat.comNeedham & Company LLC Reaffirms Buy Rating for Cytokinetics (NASDAQ:CYTK)April 11, 2025 | americanbankingnews.comNeedham & Company LLC Reiterates "Buy" Rating for Cytokinetics (NASDAQ:CYTK)Needham & Company LLC reissued a "buy" rating and set a $72.00 price target on shares of Cytokinetics in a research note on Tuesday.April 10, 2025 | marketbeat.comCytokinetics (NASDAQ:CYTK) Reaches New 52-Week Low - Should You Sell?Cytokinetics (NASDAQ:CYTK) Sets New 1-Year Low - What's Next?April 9, 2025 | marketbeat.comNeedham Sticks to Its Buy Rating for Cytokinetics (CYTK)April 9, 2025 | theglobeandmail.comCytokinetics, Incorporated (NASDAQ:CYTK) EVP Andrew Callos Sells 2,886 SharesApril 9, 2025 | insidertrades.comMassachusetts Financial Services Co. MA Sells 25,167 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)Massachusetts Financial Services Co. MA lowered its stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 7.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 319,281 shares of the biopharmaceuApril 9, 2025 | marketbeat.comInsider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells 2,886 Shares of StockCytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 2,886 shares of the company's stock in a transaction dated Monday, April 7th. The stock was sold at an average price of $35.78, for a total value of $103,261.08. Following the sale, the executive vice president now owns 64,689 shares in the company, valued at $2,314,572.42. The trade was a 4.27 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.April 9, 2025 | marketbeat.comCalifornia Public Employees Retirement System Sells 48,263 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)California Public Employees Retirement System lowered its stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 26.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 135,4April 9, 2025 | marketbeat.comFinepoint Capital LP Boosts Stake in Cytokinetics, Incorporated (NASDAQ:CYTK)Finepoint Capital LP grew its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 24.2% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 318,448 shares of the biopharmaceutical company's stock after acquiring an additional 61,999 shApril 8, 2025 | marketbeat.comSpringhill Fund Asset Management HK Co Ltd Invests $6.15 Million in Cytokinetics, Incorporated (NASDAQ:CYTK)Springhill Fund Asset Management HK Co Ltd purchased a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 130,735 shares of the biopharmaceutical company's stoApril 8, 2025 | marketbeat.comFranklin Resources Inc. Has $25.68 Million Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)Franklin Resources Inc. lifted its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 1.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 545,813 shares of the biopharmaceutiApril 8, 2025 | marketbeat.comRhenman & Partners Asset Management AB Sells 31,250 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)Rhenman & Partners Asset Management AB lowered its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 17.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investorApril 7, 2025 | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) Director Sells $17,743.50 in StockCytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) Director Robert Arthur Harrington sold 450 shares of the company's stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $39.43, for a total transaction of $17,743.50. Following the sale, the director now directly owns 14,658 shares of the company's stock, valued at approximately $577,964.94. This represents a 2.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.April 7, 2025 | marketbeat.comCytokinetics (NASDAQ:CYTK) Receives "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $120.00 price target on shares of Cytokinetics in a research note on Friday.April 6, 2025 | marketbeat.comInsider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) Director Sells 450 Shares of StockApril 6, 2025 | insidertrades.comSchroder Investment Management Group Sells 5,536,292 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)Schroder Investment Management Group decreased its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 97.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 149,433 shares of the biopharmaceutical company's stock afterApril 6, 2025 | marketbeat.comNorges Bank Takes Position in Cytokinetics, Incorporated (NASDAQ:CYTK)Norges Bank purchased a new position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 989,721 shares of the biopharmaceutical companApril 6, 2025 | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) Shares Sold by Alliancebernstein L.P.Alliancebernstein L.P. decreased its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 4.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,595,324 shares of the biopharmaceApril 5, 2025 | marketbeat.comCytokinetics (NASDAQ:CYTK) Shares Gap Up - Here's What HappenedCytokinetics (NASDAQ:CYTK) Shares Gap Up - Time to Buy?April 4, 2025 | marketbeat.comBiggest stock movers Wednesday: NCNO, TTEC, EWTX, BB, ANGO and moreApril 2, 2025 | msn.comCytokinetics stock rises following competitor’s trial resultsApril 2, 2025 | investing.comCytokinetics rises as Edgewise posts mid-stage trial data for heart disorder therapyApril 2, 2025 | msn.comWhy Edgewise Therapeutics And Cytokinetics Stocks Just DivergedApril 2, 2025 | investors.comGroupama Asset Managment Purchases Shares of 350,000 Cytokinetics, Incorporated (NASDAQ:CYTK)Groupama Asset Managment bought a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 350,000 shares of the biopharmaceutical company'sApril 2, 2025 | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) Shares Acquired by Vanguard Group Inc.Vanguard Group Inc. raised its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 1.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,915,821 shares of the bioApril 2, 2025 | marketbeat.comAmerican Century Companies Inc. Buys 27,619 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)American Century Companies Inc. lifted its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 8.4% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 356,576 shares of the biopharmaceutical company's stock after purchasing an additionApril 2, 2025 | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert I. Blum Sells 15,000 SharesCytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) CEO Robert I. Blum sold 15,000 shares of the firm's stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $40.75, for a total transaction of $611,250.00. Following the transaction, the chief executive officer now owns 427,629 shares in the company, valued at approximately $17,425,881.75. This trade represents a 3.39 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.April 1, 2025 | marketbeat.comCytokinetics (NASDAQ:CYTK) Reaches New 12-Month Low - Here's WhyCytokinetics (NASDAQ:CYTK) Sets New 52-Week Low - Here's WhyApril 1, 2025 | marketbeat.comRobert I. Blum Sells 15,000 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) StockApril 1, 2025 | insidertrades.comCytokinetics CEO Blum sells 15,000 common sharesApril 1, 2025 | markets.businessinsider.comCytokinetics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | globenewswire.comCytokinetics, Incorporated (NASDAQ:CYTK) Shares Sold by Pictet Asset Management Holding SAPictet Asset Management Holding SA reduced its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 8.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 1,911,999 shares of the biopharmaceutical company's stock after selling 176,568 shares durinMarch 31, 2025 | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) Stock Holdings Increased by WINTON GROUP LtdWINTON GROUP Ltd grew its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 94.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 19,005 shares of the biopharmaceutical compMarch 31, 2025 | marketbeat.com23,000 Shares in Cytokinetics, Incorporated (NASDAQ:CYTK) Acquired by KLP Kapitalforvaltning ASKLP Kapitalforvaltning AS purchased a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 23,000 shares of the biopharmaceutical companMarch 31, 2025 | marketbeat.comCytokinetics FY2025 EPS Estimate Lifted by Cantor FitzgeraldCytokinetics, Incorporated (NASDAQ:CYTK - Free Report) - Equities researchers at Cantor Fitzgerald upped their FY2025 EPS estimates for Cytokinetics in a research note issued on Thursday, March 27th. Cantor Fitzgerald analyst C. Duncan now forecasts that the biopharmaceutical company will earn ($March 31, 2025 | marketbeat.comWhy Cytokinetics, Incorporated (CYTK) Is the Best Mid Cap Biotech Stock to BuyMarch 30, 2025 | msn.comCorebridge Financial Inc. Sells 9,835 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)Corebridge Financial Inc. lowered its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 4.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 189,540 shares of the biopharmaceuMarch 29, 2025 | marketbeat.comVirtu Financial LLC Invests $303,000 in Cytokinetics, Incorporated (NASDAQ:CYTK)Virtu Financial LLC acquired a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 6,433 shares of the biopharmaceutical company's stock, valueMarch 29, 2025 | marketbeat.comBIT Capital GmbH Makes New $907,000 Investment in Cytokinetics, Incorporated (NASDAQ:CYTK)BIT Capital GmbH bought a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 19,283 shares of the biopharmaceutical company's stock, valued atMarch 28, 2025 | marketbeat.comCytokinetics (NASDAQ:CYTK) Trading Down 4.4% - What's Next?Cytokinetics (NASDAQ:CYTK) Shares Down 4.4% - Should You Sell?March 26, 2025 | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) Shares Bought by EFG Asset Management North America Corp.EFG Asset Management North America Corp. raised its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 145.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owneMarch 26, 2025 | marketbeat.comIs Cytokinetics, Incorporated (CYTK) a Promising Biotech Stock According to Wall Street AnalystsMarch 25, 2025 | msn.comCibc World Markets Corp Acquires New Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)Cibc World Markets Corp acquired a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 10,696 shares of the biopharmaceutical company's stock, valued at approximately $503,000.March 23, 2025 | marketbeat.com Remove Ads Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Email Address CYTK Media Mentions By Week CYTK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYTK News Sentiment▼0.710.80▲Average Medical News Sentiment CYTK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYTK Articles This Week▼2010▲CYTK Articles Average Week Remove Ads Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Teva Pharmaceutical Industries News Intra-Cellular Therapies News Genmab A/S News Dr. Reddy's Laboratories News Moderna News Ascendis Pharma A/S News Qiagen News Viatris News Roivant Sciences News Lantheus News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CYTK) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CYTK Stock Free CYTK Stock Alerts